Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

21.40 +0.18 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Schrödinger to Present at Citi Biotech Virtual Co-Panel Day
From Schrödinger, Inc.
Via Business Wire
Recap: Schrodinger Q1 Earnings
Schrodinger (NASDAQ:SDGR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Schrodinger beat estimated earnings... 
Via Benzinga
Schrödinger Reports First Quarter 2022 Financial Results
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Announce First Quarter 2022 Financial Results on May 4
From Schrödinger
Via Business Wire
Schrodinger: Q4 Earnings Insights
Schrodinger (NASDAQ:SDGR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Preview: Schrodinger's Earnings
Schrodinger (NASDAQ:SDGR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Why Jim Cramer Recommends Selling AGNC Investment
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Schrodinger Inc (NYSE: 
Via Benzinga
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
AI Pharma Startup METiS Raises $150 Million. IPO In Sight?
Key takeaways: METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million The company was... 
Via Benzinga
Schrödinger New Preclinical Data Supports Development Of Its Wee1 Inhibitor In Cancer Indications
Schrödinger Inc (NASDAQ: SDGR)  
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Schrödinger Reports New Preclinical Data Supporting Advancement of Its Wee1 Inhibitor Program at American Association of Cancer Research 2022 Annual Meeting
From Schrödinger, Inc.
Via Business Wire
3 Hypergrowth Tech Stocks to Buy for Huge Upside Potential
These hypergrowth stocks are bargains after retreating for much of the last year. They will all perform very well for long-term investors. 
Via InvestorPlace
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Aerie Pharmaceuticals (NASDAQ:AERI) shares increased by 28.1% to $7.56 during Friday's regular session. Trading volume for Aerie Pharmaceuticals's stock is... 
Via Benzinga
93 Biggest Movers From Friday
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90. Guardforce AI Co., Limited (NASDAQ: GFAI) jumped 45.4% to settle at $0.5979 on Friday. EF... 
Via Benzinga
45 Stocks Moving In Friday's Mid-Day Session
Gainers KAR Auction Services, Inc. (NYSE: KAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2... 
Via Benzinga
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021
From Schrödinger, Inc.
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Schrödinger to Announce Fourth Quarter and Full-Year 2021 Financial Results on February 24
From Schrödinger
Via Business Wire
Schrödinger to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
Schrödinger Announces Acquisition of XTAL BioStructures, Inc.
From Schrödinger, Inc.
Via Business Wire
Schrödinger to Present at H.C. Wainwright BioConnect Conference
From Schrödinger, Inc.
Via Business Wire
Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz
From Schrödinger, Inc.
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger, Inc.
Via Business Wire
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hematology 2021 Annual Meeting
From Schrödinger
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback